Abbonarsi

Délai d’obtention d’une première décision finale par un Comité de Protection des Personnes pour débuter une étude de recherche clinique en France : Etude rétrospective entre 2019 et 2023 - 15/08/24

Time for assessing a clinical research project by one of 39 French ethic committees: A retrospective study between 2019 and 2023

Doi : 10.1016/j.revmed.2024.07.009 
S. Roriz a, , C. Michel a, M. Mezzarobba a, M. Grit b, c, G. Baville Valade b, E. Cabrera b, L. ElotmanI a, A. Ambert a, J.-Y. Lefrant a, b, S. Granier b, d, N. Boulet a, Y. Gricourt a
a UR-UM103 IMAGINE, Univ Montpellier, Division of Anesthesia Critical Care, Pain and Emergency Medicine, Nîmes University Hospital, Montpellier, France 
b Comité de Protection des Personnes Sud Méditerranée III, CHU de Nîmes – Site de Serre Cavalier, place du Pr Robert Debré, 30029 Nîmes Cedex 9, France 
c Responsable juridique, GRADeS e-santé, 10, rue des trente-six ponts, 31400 Toulouse, France 
d Direction de la recherche clinique et de l’innovation, CHU de Nîmes, place du Pr Robert Debré, 30029 Nîmes Cedex 9, France 

Auteur correspondant. UR-UM103 IMAGINE, Univ Montpellier, Division of Anesthesia Critical Care, Pain and Emergency Medicine, Nîmes University Hospital, Montpellier, France, CHU de Nîmes, place du Pr Robert Debré, 30029 Nîmes Cedex 9, France.UR-UM103 IMAGINE, Univ Montpellier, Division of Anesthesia Critical Care, Pain and Emergency Medicine, Nîmes University Hospital, Montpellier, France, CHU de Nîmesplace du Pr Robert DebréNîmes Cedex 930029France
In corso di stampa. Prove corrette dall'autore. Disponibile online dal Thursday 15 August 2024

Résumé

Introduction

Cette étude rapporte le temps d’évaluation des projets de recherche soumis à l’un des 39 CPP français entre le dépôt initial et la décision finale. Les délais de première inclusion et de réalisation de l’étude étaient aussi analysés.

Méthode

Chaque projet soumis entre le 1/01/2019 et le 30/06/2023, a été analysé selon le type d’études (recherches sur le médicament, investigations cliniques, étude de performances, recherche impliquant la personne humaine) et de promoteur (industriel, institutions hospitalières universitaires, non universitaires, privée, autres). Le délai d’évaluation du projet (objectif principal) était calculé entre le dépôt initial et l’émission de l’avis final. Les délais de première inclusion (entre acceptation finale et première inclusion) et de réalisation de l’étude (entre première et dernière inclusion) ont été calculés.

Résultats

Parmi les 467 projets analysés, 424 ont obtenu un avis favorable (90,8 %). La valeur médiane (25e–75e percentiles) du délai d’évaluation était de 73jours [51–98] sans différence selon le type d’étude et le type de promotion. Pour 307 projets, la première inclusion avait eu lieu après 134jours [61–237] et, pour 39 autres, était en attente depuis 347jours [306–510]. Pour 122 projets, le délai de réalisation était de 446jours [230–731] et pour 185 autres, les inclusions étaient toujours en cours depuis 699jours [397–1098].

Conclusion

Le CPP étudié émettait une décision finale (plus de 90 % d’avis favorable) après un délai médian de 73jours, inférieur aux délais de première inclusion et de réalisation de l’étude.

Il testo completo di questo articolo è disponibile in PDF.

Abstract

Introduction

The study reported the time (from the initial submission to the final decision) to evaluate a clinical research project by one of the 39 French national ethics committees. The times from this final decision to the first participant inclusion and study achievement (first patient inclusion to the end of the last patient's follow-up) were also reported.

Methods

Clinical research projects submitted between January 1st 2019 and June 30th 2023 were analyzed according to their type (research on drugs, clinical investigations, performance studies, research implying human person), and the promotor (industry, university hospital, general hospital, private medical institution, others). The times of assessment of the project by the ethic committee (from the initial submission to the final decision), of the first participant inclusion (from the approval of the project) and of study achievement (first patient inclusion to the end of the last patient's follow-up) were calculated.

Results

Among 467 submitted clinical research projects, 424 were approved (90.8 %). The median time [Q1–Q3] to evaluate a project was 73 days [51–98] whatever the types of projects and promotors. In 307 accepted projects, the first patient inclusion occurred after 134 days [61–237] and was being waited for 347 days [306–510] in 39 other ones. In 122 projects, the time for study achievement was 446 days [230–731]. In 185 other projects, the inclusions were still in progress for 699 days [397–1098].

Conclusion

In this concerned ethic committee, a final decision was edited after a median assessment time of 73 days (with >90 % approvals), shorter than the times to include the first patient and for achieving the study.

Il testo completo di questo articolo è disponibile in PDF.

Mots clés : Recherche clinique, Comité d’éthique

Keywords : Clinical research, Ethic committee


Mappa


© 2024  Pubblicato da Elsevier Masson SAS.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2024 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.